Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study
Marta Bravo Peña, Giulia Losi, Vı́ctor Navarro, David Qualls et autres
3 citationsBlood Advances
David Qualls
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
62Publications signalées
716Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentCAR-T cell therapy researchChronic Lymphocytic Leukemia ResearchMonoclonal and Polyclonal Antibodies ResearchCNS Lymphoma Diagnosis and Treatment
Publications récentes
Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab
Hari S. Raman, Robert Redd, Inhye E. Ahn, Amy Bessnow et autres
0 citationsBlood
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Austin Kim, Peter A. Riedell, Christine E. Ryan, Robert Redd et autres
8 citationsBlood
Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)
Matthew J. Frank, David Qualls, Armin Ghobadi, Jordan Gauthier et autres
0 citationsBlood
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial
Reid W. Merryman, Gottfried von Keudell, Robert Redd, Heather Walker et autres
0 citationsBlood
Clinical use of genome-wide hi-c sequencing for assessment of structural variants in diffuse large B-cell lymphoma
Phillip Michaels, David Qualls, Anthony D. Schmitt, Alex Hastie
0 citationsBlood
Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study
David Qualls, Andrew Jallouk, Geoffrey Shouse, Omnia Farahat et autres
0 citationsBlood
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial
Reid W. Merryman, Danielle Wallace, Robert Redd, Heather Walker et autres
0 citationsBlood
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
Mwanasha H. Merrill, Robert Redd, Nicholas Lambert, Paolo F. Caimi et autres
1 citationHemaSphere
91 | BMS‐986458, A FIRST‐IN‐CLASS, BIFUNCTIONAL CEREBLON‐DEPENDENT LIGAND‐DIRECTED DEGRADER (LDD) OF B‐CELL LYMPHOMA 6 (BCL6) IN PATIENTS WITH R/R NHL: INITIAL PH 1 RESULTS
F. Morschhauser, David Qualls, Jennifer Kimberly Lue, Anastasios Stathis et autres
0 citationsHematological Oncology
227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL
R. Merryman, D. S. Wallace, Robert Redd, Hamish Walker et autres
1 citationHematological Oncology
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
Jennifer L. Crombie, Robert Redd, Michael Forsyth, Chris Carey et autres
3 citationsHematological Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.